The immunosuppressant FK506 promotes development of the chondrogenic phenotype in human synovial stromal cells via modulation of the Smad signaling pathway

Osteoarthritis and Cartilage

Volumn 15, Issue 6, 2007, Pages 709-718

  Tateishi, K ^a   Higuchi, C ^a   Ando, W ^a   Nakata, K ^a   Hashimoto, J ^a   Hart, D A ^b   Yoshikawa, H ^a   Nakamura, N ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

BMP; Cartilage repair; FK506; Synovium; TGF ; Tissue engineering

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; GLYCOSAMINOGLYCAN; GROWTH FACTOR; IMMUNOSUPPRESSIVE AGENT; MESSENGER RNA; PROTEOGLYCAN; SMAD PROTEIN; SMAD1 PROTEIN; SMAD3 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ANTERIOR CRUCIATE LIGAMENT INJURY; ARTICLE; CASE REPORT; CELL DIFFERENTIATION; CELL ISOLATION; CHONDROGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOPLASM; DRUG ACTIVITY; DRUG EFFECT; DRUG EXPOSURE; FEMALE; GLYCOSAMINOGLYCAN METABOLISM; HUMAN; HUMAN CELL; MALE; OSTEOCHONDRITIS DISSECANS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STROMA CELL; SYNOVIOCYTE; SYNOVIUM;

ADULT; CARTILAGE, ARTICULAR; CHONDROCYTES; CHONDROGENESIS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PHENOTYPE; SIGNAL TRANSDUCTION; SMAD PROTEINS; STROMAL CELLS; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 34248594901     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2007.01.006     Document Type: Article

References (45)

1. Haywood L., and Walsh D.A. Vasculature of the normal and arthritic synovial joint. Histol Histopathol 16 (2001) 277-284
2. Brittberg M., Lindahl A., Nilsson A., Ohlsson C., Isaksson O., and Peterson L. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N Engl J Med 331 (1994) 889-895
3. Brittberg M., Peterson L., Sjogren-Jansson E., Tallheden T., and Lindahl A. Articular cartilage engineering with autologous chondrocyte transplantation. A review of recent developments. J Bone Joint Surg Am 85-A Suppl 3 (2003) 109-115
4. Horas U., Pelinkovic D., Herr G., Aigner T., and Schnettler R. Autologous chondrocyte implantation and osteochondral cylinder transplantation in cartilage repair of the knee joint. A prospective, comparative trial. J Bone Joint Surg Am 85-A (2003) 185-192
5. Benya P.D., Padilla S.R., and Nimni M.E. The progeny of rabbit articular chondrocytes synthesize collagen types I and III and type I trimer, but not type II. Verifications by cyanogen bromide peptide analysis. Biochemistry 16 (1977) 865-872
6. Benya P.D., Padilla S.R., and Nimni M.E. Independent regulation of collagen types by chondrocytes during the loss of differentiated function in culture. Cell 15 (1978) 1313-1321
7. Archer C.W., McDowell J., Bayliss M.T., Stephens M.D., and Bentley G. Phenotypic modulation in sub-populations of human articular chondrocytes in vitro. J Cell Sci 97 Pt 2 (1990) 361-371
8. Mayhew T.A., Williams G.R., Senica M.A., Kuniholm G., and Du Moulin G.C. Validation of a quality assurance program for autologous cultured chondrocyte implantation. Tissue Eng 4 (1998) 325-334
9. Minas T., and Bryant T. The role of autologous chondrocyte implantation in the patellofemoral joint. Clin Orthop 436 (2005) 30-39
10. Bruder S.P., Fink D.J., and Caplan A.I. Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy. J Cell Biochem 56 (1994) 283-294
11. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 284 (1999) 143-147
12. Lee O.K., Kuo T.K., Chen W.M., Lee K.D., Hsieh S.L., and Chen T.H. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood 103 (2004) 1669-1675
13. Jankowski R.J., Deasy B.M., and Huard J. Muscle-derived stem cells. Gene Ther 9 (2002) 642-647
14. Zuk P.A., Zhu M., Mizuno H., Huang J., Futrell J.W., Katz A.J., et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 7 (2001) 211-228
15. Dragoo J.L., Samimi B., Zhu M., Hame S.L., Thomas B.J., Lieberman J.R., et al. Tissue-engineered cartilage and bone using stem cells from human infrapatellar fat pads. J Bone Joint Surg Br 85 (2003) 740-747
16. Salingcarnboriboon R., Yoshitake H., Tsuji K., Obinata M., Amagasa T., Nifuji A., et al. Establishment of tendon-derived cell lines exhibiting pluripotent mesenchymal stem cell-like property. Exp Cell Res 287 (2003) 289-300
17. De Bari C., Dell'Accio F., Tylzanowski P., and Luyten F.P. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum 44 (2001) 1928-1942
18. Fickert S., Fiedler J., and Brenner R.E. Identification, quantification and isolation of mesenchymal progenitor cells from osteoarthritic synovium by fluorescence automated cell sorting. Osteoarthritis Cartilage 11 (2003) 790-800
19. Sakaguchi Y., Sekiya I., Yagishita K., and Muneta T. Comparison of human stem cells derived from various mesenchymal tissues: superiority of synovium as a cell source. Arthritis Rheum 52 (2005) 2521-2529
20. Ho S., Clipstone N., Timmermann L., Northrop J., Graef I., Fiorentino D., et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 80 (1996) S40-S45
21. Ranger A.M., Gerstenfeld L.C., Wang J., Kon T., Bae H., Gravallese E.M., et al. The nuclear factor of activated T cells (NFAT) transcription factor NFATp (NFATc2) is a repressor of chondrogenesis. J Exp Med 191 (2000) 9-22
22. Tomita M., Reinhold M.I., Molkentin J.D., and Naski M.C. Calcineurin and NFAT4 induce chondrogenesis. J Biol Chem 277 (2002) 42214-42218
23. Nishigaki F., Sakuma S., Ogawa T., Miyata S., Ohkubo T., and Goto T. FK506 induces chondrogenic differentiation of clonal mouse embryonic carcinoma cells, ATDC5. Eur J Pharmacol 437 (2002) 123-128
24. Johnstone B., Hering T.M., Caplan A.I., Goldberg V.M., and Yoo J.U. In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells. Exp Cell Res 238 (1998) 265-272
25. Sekiya I., Vuoristo J.T., Larson B.L., and Prockop D.J. In vitro cartilage formation by human adult stem cells from bone marrow stroma defines the sequence of cellular and molecular events during chondrogenesis. Proc Natl Acad Sci U S A 99 (2002) 4397-4402
26. Karran E.H., Young T.J., Markwell R.E., and Harper G.P. In vivo model of cartilage degradation-effects of a matrix metalloproteinase inhibitor. Ann Rheum Dis 54 (1995) 662-669
27. Higuchi C., Myoui A., Hashimoto N., Kuriyama K., Yoshioka K., Yoshikawa H., et al. Continuous inhibition of MAPK signaling promotes the early osteoblastic differentiation and mineralization of the extracellular matrix. J Bone Miner Res 17 (2002) 1785-1794
28. Gruendler C., Lin Y., Farley J., and Wang T. Proteasomal degradation of Smad1 induced by bone morphogenetic proteins. J Biol Chem 276 (2001) 46533-46543
29. Furumatsu T., Tsuda M., Taniguchi N., Tajima Y., and Asahara H. Smad3 induces chondrogenesis through the activation of SOX9 via CREB-binding protein/p300 recruitment. J Biol Chem 280 (2005) 8343-8350
30. Lamb T.M., Knecht A.K., Smith W.C., Stachel S.E., Economides A.N., Stahl N., et al. Neural induction by the secreted polypeptide noggin. Science 262 (1993) 713-718
31. Laping N.J., Grygielko E., Mathur A., Butter S., Bomberger J., Tweed C., et al. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol 62 (2002) 58-64
32. Jadlowiec J.A., Zhang X., Li J., Campbell P.G., and Sfeir C. Extracellular matrix-mediated signaling by dentin phosphophoryn involves activation of the Smad pathway independent of bone morphogenetic protein. J Biol Chem 281 (2006) 5341-5347
33. Inman G.J., Nicolas F.J., Callahan J.F., Harling J.D., Gaster L.M., Reith A.D., et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 62 (2002) 65-74
34. Sekiya I., Colter D.C., and Prockop D.J. BMP-6 enhances chondrogenesis in a subpopulation of human marrow stromal cells. Biochem Biophys Res Commun 284 (2001) 411-418
35. Shi Y., and Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113 (2003) 685-700
36. Hatakeyama Y., Nguyen J., Wang X., Nuckolls G.H., and Shum L. Smad signaling in mesenchymal and chondroprogenitor cells. J Bone Joint Surg Am 85-A Suppl 3 (2003) 13-18
37. Persson U., Souchelnytskyi S., Franzen P., Miyazono K., ten Dijke P., and Heldin C.H. Transforming growth factor (TGF-beta)-specific signaling by chimeric TGF-beta type II receptor with intracellular domain of activin type IIB receptor. J Biol Chem 272 (1997) 21187-21194
38. Fujii M., Takeda K., Imamura T., Aoki H., Sampath T.K., Enomoto S., et al. Roles of bone morphogenetic protein type I receptors and Smad proteins in osteoblast and chondroblast differentiation. Mol Biol Cell 10 (1999) 3801-3813
39. Huse M., Chen Y.G., Massague J., and Kuriyan J. Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12. Cell 96 (1999) 425-436
40. Kugimiya F., Yano F., Ohba S., Igawa K., Nakamura K., Kawaguchi H., et al. Mechanism of osteogenic induction by FK506 via BMP/Smad pathways. Biochem Biophys Res Commun 338 (2005) 872-879
41. Oh C.D., Chang S.H., Yoon Y.M., Lee S.J., Lee Y.S., Kang S.S., et al. Opposing role of mitogen-activated protein kinase subtypes, erk-1/2 and p38, in the regulation of chondrogenesis of mesenchymes. J Biol Chem 275 (2000) 5613-5619
42. Han Y.S., Bang O.S., Jin E.J., Park J.H., Sonn J.K., and Kang S.S. High dose of glucose promotes chondrogenesis via PKCalpha and MAPK signaling pathways in chick mesenchymal cells. Cell Tissue Res 318 (2004) 571-578
43. Oh C.D., and Chun J.S. Signaling mechanisms leading to the regulation of differentiation and apoptosis of articular chondrocytes by insulin-like growth factor-1. J Biol Chem 278 (2003) 36563-36571
44. Curran C.F., Blahunka P.C., and Lawrence I.D. Acute overdoses of tacrolimus. Transplantation 62 (1996) 1376-1377
45. Ormerod A.D. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?. Br J Dermatol 153 (2005) 701-705